Fentanyl, Alprazolam, and a First Buprenorphine Visit
Danny, 29, has smoked illicitly manufactured fentanyl (about 1–2 g/day) for two years and wants to start buprenorphine today at your outpatient clinic. He last used 8 hours ago and is in mild withdrawal (COWS 9). He also takes alprazolam 1 mg twice daily, prescribed by an outside psychiatrist for panic attacks; he denies nonmedical use, and his urine is positive for fentanyl and benzodiazepines. He lives 45 minutes from the clinic with no reliable transportation and has a 6-year-old daughter at home. He has been hospitalized twice for overdose in the past 18 months. He asks, "Can't I just keep using until the buprenorphine kicks in?"
1. Compare standard induction with low-dose (overlapping) induction for this patient, and justify a plan.
Read the worked answer
Why this is not a routine induction.
- Illicitly manufactured fentanyl is highly lipophilic with a long, variable tissue half-life. Standard induction (waiting 12–24 hours and dosing when COWS is elevated) carries a substantial risk of precipitated withdrawal in this population.
- He is only 8 hours out with moderate symptoms, so his withdrawal will likely deepen over the next day or two.
Option A - standard induction, delayed. Wait 48–72 hours, reassess COWS repeatedly, and start with small doses (2 mg), titrating. Safer regarding precipitated withdrawal only if he can genuinely abstain long enough and can be reached.
Option B - low-dose induction. Begin very small buprenorphine doses (e.g., 0.5 mg, often via transmucosal or transdermal routes) while he continues full-agonist use, escalating over several days to a therapeutic dose, then tapering the fentanyl. This lowers precipitated-withdrawal risk but requires continued illicit use, which is dangerous given two overdoses.
Selection. Given overdose history and access barriers, either is defensible, but whichever is chosen must be paired with same-day naloxone, a clear written dosing schedule, daily or near-daily contact (telehealth acceptable), and a defined transition point. Do not send him home with no plan because he "isn't ready" for standard induction.
2. How do you manage the alprazolam in relation to starting buprenorphine?
Read the worked answer
Start the buprenorphine; do not make the benzodiazepine a gate.
- Withholding buprenorphine because of concurrent benzodiazepine use increases overdose and dropout risk. Buprenorphine should be offered.
- Simultaneously, benzodiazepine plus buprenorphine carries a boxed warning for respiratory depression and sedation, so the combination requires explicit risk mitigation rather than silence.
Benzodiazepine plan.
- Do not stop alprazolam abruptly - 2 mg/day chronic use means abrupt discontinuation risks withdrawal and seizures.
- Obtain a release and coordinate with the prescribing psychiatrist: one prescriber for benzodiazepines, a slow taper only after he is stabilized on buprenorphine, no escalating quantities, no other sedatives or alcohol.
- Avoid becoming the second sedative prescriber; if you must bridge, use limited quantities, a single pharmacy, and documented shared decision-making about risk.
Monitoring. Education on sedation and overdose, never-use-alone guidance, naloxone to him and to a household member, and caution that both buprenorphine and alprazolam must be stored locked away from the 6-year-old.
3. What safety and engagement plan addresses his two prior overdoses and his distance from the clinic?
Read the worked answer
Match intensity to risk.
- Two overdoses in 18 months is a high-risk marker. Consider a higher-intensity induction setting (e.g., partial hospital or residential, ASAM 2.5/3.2/3.7) or, if outpatient, an induction model with close observation and structured follow-up.
Barriers. The 45-minute drive without reliable transport will sink a daily-visit plan. Options: home or telehealth induction with video dosing checks where permissible, pharmacy delivery, a longer-acting formulation if he stabilizes, and a backup contact number. Identify who can drive him and build the schedule around that.
Harm reduction. Naloxone, fentanyl test strips, never-use-alone, and clear instructions to call emergency services. Give written instructions for missed doses and what to do if he uses while on buprenorphine. Review safe storage with a child in the home for all medications.
Engagement. Set a specific follow-up within 48–72 hours regardless of whether he uses; frame continued use as information to adjust the plan rather than grounds for discharge. Address child care as a real barrier rather than a compliance failure.